Stockwinners Market Radar for November 18, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:29 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. PG&E (PCG), facing investor concerns over its possible role in the deadly Camp Fire in Northern California, has reported another power-line outage that it experienced on the morning of November 8 when the blaze started, according to Reuters. The incident report said a line near the area of Concow in Butte County suffered an outage at 6:45 a.m. on November 8, the publication noted. 2. After CBS (CBS) CEO Les Moonves' downfall on sexual-assault allegations, insiders said the TV giant's board could announce a merger with Viacom (VIAB) in the next three to six months, a deal that Moonves had fiercely resisted, according to The New York Post. "I would be surprised if we are sitting around in March and CBS and Viacom are not combined," said one media executive close to the situation. 3. Store chains have been learning lessons from Amazon's (AMZN) success and investing in e-commerce fulfillment, and for stores that struggle now, the problem is them, not the economy or Amazon, Jack Hough wrote in this week's edition of Barron's. To find likely winners, stock investors should be cautious of malls, and of stores with a shortage of unique merchandise, while being bullish on those with digital savvy, the publication noted. Kohl's (KSS) and Target (TGT) appear poised to outperform, and Home Depot (HD) and Tiffany (TIF) are worth their premium valuations, while Best Buy (BBY) has had a heroic run, but now faces especially difficult sales comparisons versus last year, Hough contended. TJX (TJX) could cool, too and the outlook is not promising for J.C. Penney (JCP) and L Brands (LB), he added. 4. AT&T (T) subsidiary Warner Bros' "Fantastic Beasts: The Crimes of Grindelwald" debuted to $62.2M from 4,163 theaters. Overseas, the movie roared to $191M from 79 markets. The sequel earned a B+ CinemaScore and sports a 40% Rotten Tomatoes score. 5. BP (BP), Chevron (CVX), ExxonMobil (XOM), Royal Dutch Shell (RDS.A), Anadarko Petroleum (APC), EOG Resources (EOG), Occidental Petroleum (OXY), Cabot Oil & Gas (COG), EQT (EQT), Halliburton (HAL), Schlumberger (SLB), Amgen (AMGN), and Treehouse Foods (THS) saw positive mentions in Barron's, while Apple (AAPL) was mentioned cautiously.

16:51 EDT PALISADE trial of Aimmune's AR101 published in New England Journal of Medicine - Aimmune Therapeutics announced that the New England Journal of Medicine has published the full results of the landmark phase 3 PALISADE clinical trial of AR101, Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. PALISADE is the largest and first successful phase 3 peanut allergy immunotherapy trial to date. As reported in the NEJM article, "AR101 Oral Immunotherapy for Peanut Allergy,"1 PALISADE met its primary endpoint and key secondary endpoints. In the trial's primary analysis of peanut-allergic children and adolescents ages 4-17, AR101 treatment resulted in a significant increase in the amount of peanut protein tolerated, compared to placebo. The increase, which was measured through a series of doses in an exit food challenge, suggests that AR101-treated patients could expect to have protection against reactions to accidental peanut exposures. In a real-world translation of the amounts of peanut protein tolerated, 67% of AR101 patients tolerated a single dose of at least 2 peanuts; among AR101 patients who completed the trial, 85% tolerated this level, which is equivalent to 3-4 peanuts of total exposure. Also, 50% of AR101 patients tolerated the highest challenge level, a single dose equivalent to 3-4 peanuts. AR101 treatment also resulted in a reduction in the number and severity of reactions in the exit food challenge, compared to placebo. In the exit challenge,10% of AR101 patients received epinephrine, and the median dose at which it was given was 1,000 mg of peanut protein, compared to 53% of placebo patients at a median dose of 100 mg. This corresponds to an overall 81% reduction in epinephrine use in AR101 patients across all levels of the exit challenge, with a 99% reduction at the 300-mg level and a 94% reduction at the 600-mg level. AR101 demonstrated a favorable safety profile in the highly atopic patient population enrolled in PALISADE. Treatment-emergent adverse events occurred in more than 95% of patients in both trial groups, and nearly all were mild or moderate in severity. In AR101 patients who experienced treatment-related adverse events, 2.4% experienced severe adverse events and 1.1% experienced serious adverse events. Epinephrine was used for severe adverse events in two patients, one of which was the single case of anaphylaxis in the trial.

15:21 EDT AT&T, Fox Networks renew multi-year deal across distribution platforms - AT&T (T) and Fox Networks Group (FOXA) have renewed a multi-year deal to continue distribution of Fox programming across AT&T's video platforms DIRECTV, DIRECTV NOW and AT&T U-verse. The renewal includes Fox-owned local broadcast stations in 17 cities and the 22 Fox-owned regional sports networks. It also includes FS1, FS2, FX, FXX, FXM, National Geographic Channel, Nat Geo Wild, BabyTV, and Spanish-language services Fox Deportes, Nat Geo Mundo and Fox Life, as well as the Fox Soccer Plus pay-per-view service.